Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

325 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Randomized double blind trial of an ayurvedic plant derived formulation for treatment of rheumatoid arthritis.
Chopra A, Lavin P, Patwardhan B, Chitre D. Chopra A, et al. J Rheumatol. 2000 Jun;27(6):1365-72. J Rheumatol. 2000. PMID: 10852255 Clinical Trial.
An intent-to-treat analysis was performed; p<0.05 considered significant. RESULTS: Seventeen patients withdrew (active = 9; placebo = 8); none withdrew due to drug toxicity. An unprecedented placebo response (often p<0.001 in within-group change) was observed. …
An intent-to-treat analysis was performed; p<0.05 considered significant. RESULTS: Seventeen patients withdrew (active = 9; placeb …
A multicenter, randomized controlled trial comparing a single intra-articular injection of Gel-200, a new cross-linked formulation of hyaluronic acid, to phosphate buffered saline for treatment of osteoarthritis of the knee.
Strand V, Baraf HSB, Lavin PT, Lim S, Hosokawa H. Strand V, et al. Osteoarthritis Cartilage. 2012 May;20(5):350-356. doi: 10.1016/j.joca.2012.01.013. Epub 2012 Feb 1. Osteoarthritis Cartilage. 2012. PMID: 22342928 Clinical Trial.
Effectiveness of Gel-200 by WOMAC pain subscores was statistically significant at week 13 (P=0.037). Mean improvements from baseline in WOMAC pain subscores consistently favored Gel-200 at each visit. Effectiveness of Gel-200 treatment was statistically significant over we …
Effectiveness of Gel-200 by WOMAC pain subscores was statistically significant at week 13 (P=0.037). Mean improvements from baseline …
A 32-week randomized, placebo-controlled clinical evaluation of RA-11, an Ayurvedic drug, on osteoarthritis of the knees.
Chopra A, Lavin P, Patwardhan B, Chitre D. Chopra A, et al. J Clin Rheumatol. 2004 Oct;10(5):236-45. doi: 10.1097/01.rhu.0000138087.47382.6d. J Clin Rheumatol. 2004. PMID: 17043520
RESULTS: 1) EFFICACY: Compared with placebo, the mean reduction in pain VAS at week 16 (active = 2.7, placebo = 1.3) and week 32 (active = 2.8, placebo = 1.8) in the active group was significantly (P <0.05, analysis of variance [ANOVA]) better. Similarly, the improvemen …
RESULTS: 1) EFFICACY: Compared with placebo, the mean reduction in pain VAS at week 16 (active = 2.7, placebo = 1.3) and week 32 (active = 2 …
Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study.
Carr DB, Goudas LC, Denman WT, Brookoff D, Staats PS, Brennen L, Green G, Albin R, Hamilton D, Rogers MC, Firestone L, Lavin PT, Mermelstein F. Carr DB, et al. Pain. 2004 Mar;108(1-2):17-27. doi: 10.1016/j.pain.2003.07.001. Pain. 2004. PMID: 15109503 Clinical Trial.

Patients reported significantly lower BTP intensity following intranasal ketamine than after placebo (P < 0.0001) with pain relief within 10 min of dosing and lasting for up to 60 min. No patient in the ketamine group required his/her usual rescue medication to treat th

Patients reported significantly lower BTP intensity following intranasal ketamine than after placebo (P < 0.0001) with pain relief

Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.
Anker SD, Kosiborod M, Zannad F, Piña IL, McCullough PA, Filippatos G, van der Meer P, Ponikowski P, Rasmussen HS, Lavin PT, Singh B, Yang A, Deedwania P. Anker SD, et al. Eur J Heart Fail. 2015 Oct;17(10):1050-6. doi: 10.1002/ejhf.300. Epub 2015 Jun 16. Eur J Heart Fail. 2015. PMID: 26011677 Free PMC article. Clinical Trial.
Despite RAASi doses being kept constant, patients on 5 g, 10 g, and 15 g ZS-9 maintained a lower potassium level (4.7 mmol/L, 4.5 mmol/L, and 4.4 mmol/L, respectively) than the placebo group (5.2 mmol/L; P<0.01 vs. each ZS-9 group); greater proportions of ZS-9 patients …
Despite RAASi doses being kept constant, patients on 5 g, 10 g, and 15 g ZS-9 maintained a lower potassium level (4.7 mmol/L, 4.5 mmol/L, an …
Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. ORTHOVISC Study Group.
Brandt KD, Block JA, Michalski JP, Moreland LW, Caldwell JR, Lavin PT. Brandt KD, et al. Clin Orthop Relat Res. 2001 Apr;(385):130-43. doi: 10.1097/00003086-200104000-00021. Clin Orthop Relat Res. 2001. PMID: 11302304 Clinical Trial.
Effectiveness and Safety of a Multicenter Extension and Retreatment Trial of Gel-200 in Patients with Knee Osteoarthritis.
Strand V, Baraf HS, Lavin PT, Lim S, Hosokawa H. Strand V, et al. Cartilage. 2012 Oct;3(4):297-304. doi: 10.1177/1947603512451024. Cartilage. 2012. PMID: 26069640 Free PMC article.

RESULTS: In the extension phase, time-to-event analyses through 26 weeks following the initial injection showed statistically significantly longer times to retreatment in patients receiving Gel-200 compared with PBS (P < 0.05). Retreatment with Gel-200, e.g., a second i

RESULTS: In the extension phase, time-to-event analyses through 26 weeks following the initial injection showed statistically significantly …
Safety and efficacy of intranasal ketamine in a mixed population with chronic pain.
Carr DB, Goudas LC, Denman WT, Brookoff D, Lavin PT, Staats PS. Carr DB, et al. Pain. 2004 Aug;110(3):762-4. doi: 10.1016/j.pain.2004.04.014. Pain. 2004. PMID: 15288418 No abstract available.
Partial liquid ventilation in adult patients with acute respiratory distress syndrome.
Kacmarek RM, Wiedemann HP, Lavin PT, Wedel MK, Tütüncü AS, Slutsky AS. Kacmarek RM, et al. Am J Respir Crit Care Med. 2006 Apr 15;173(8):882-9. doi: 10.1164/rccm.200508-1196OC. Epub 2005 Oct 27. Am J Respir Crit Care Med. 2006. PMID: 16254269 Clinical Trial.
RESULTS: The 28-d mortality in the CMV group was 15%, versus 26.3% in the low-dose (p=0.06) and 19.1% in the high-dose (p=0.39) PLV groups. There were more ventilator-free days in the CMV group (13.0+/-9.3) compared with both the low-dose (7.4+/-8.5; p<0.0 …
RESULTS: The 28-d mortality in the CMV group was 15%, versus 26.3% in the low-dose (p=0.06) and 19.1% in the high-dose (p=0.39 …
Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.
Spinowitz BS, Fishbane S, Pergola PE, Roger SD, Lerma EV, Butler J, von Haehling S, Adler SH, Zhao J, Singh B, Lavin PT, McCullough PA, Kosiborod M, Packham DK; ZS-005 Study Investigators. Spinowitz BS, et al. Clin J Am Soc Nephrol. 2019 Jun 7;14(6):798-809. doi: 10.2215/CJN.12651018. Epub 2019 May 20. Clin J Am Soc Nephrol. 2019. PMID: 31110051 Free PMC article.
325 results
Jump to page
Feedback